FDA Fast Tracks Novel Inhibitor for BRCA-Mutant Breast Cancer

The FDA has granted fast track designation (FTD) to ART6043, a first-in-class small molecule inhibitor of DNA polymerase theta (Polθ), for the treatment of patients with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. This designation is intended to expedite the development and review of the investigational agent in a patient population with high unmet medical needs.¹

The FDA’s decision was supported by preliminary clinical data from an ongoing first-in-human phase 1/2a multicenter study (NCT05898399).² In data presented at the ESMO Congress 2025, ART6043 demonstrated a favorable safety and tolerability profile, alongside evidence of target engagement and early antitumor activity.¹

“Breast cancer remains the second leading cause of cancer death in women in the United States. Granting of US [FTD] is an important recognition of ART6043’s clinical profile to treat [germline BRCA-mutated] HER2-negative breast cancer and supports our mission to rapidly deliver potential first-in-class therapies to patients who have limited treatment options,” said Mike Andriole, CEO of Artios Pharma, in a news release. “Importantly, [patients with breast cancer] with a BRCA mutation often develop resistance to treatment with a PARP inhibitor alone. There remains a significant need to improve clinical outcomes and rates of survival through inhibition of Polθ.”

Mechanism of Action and Synthetic Lethality

ART6043 represents a novel approach within the DNA damage response (DDR) landscape. The drug is a selective, orally bioavailable inhibitor of the polymerase domain of Polθ, an enzyme primarily involved in microhomology-mediated end-joining (MMEJ), also known as theta-mediated end-joining. While Polθ is virtually absent in healthy tissues, it is frequently overexpressed in various malignancies, where it serves as a critical alternative DNA repair pathway when other mechanisms, such as homologous recombination (HR), are compromised.

In BRCA-deficient cells, the HR pathway is dysfunctional, forcing the cell to rely heavily on Polθ-mediated MMEJ to repair double-strand breaks. By inhibiting Polθ in these cells, ART6043 induces synthetic lethality, a process where the simultaneous loss of 2 pathways leads to cell death, whereas the loss of either alone is nonlethal. This mechanism provides a clear biological rationale for targeting BRCA-mutated cancers while potentially sparing normal tissue from systemic toxicity.

Clinical Evaluation and ESMO 2025 Data

The ongoing phase 1/2a trial is evaluating ART6043 both as a monotherapy and in combination with the PARP inhibitor olaparib (Lynparza). The study includes patients with advanced solid tumors harboring various DDR defects. Preliminary results presented at ESMO 2025 highlighted that the combination therapy was well-tolerated at investigated doses, with a pharmacokinetic profile supporting twice-daily oral administration.

Notably, clinical signals were observed in patients with BRCA-mutated HER2-negative breast cancer, including those who had previously progressed on PARP inhibitors. Resistance to PARP inhibitors remains a significant clinical challenge in the management of BRCA-mutant breast cancer, often driven by the restoration of HR or the upregulation of alternative repair pathways like MMEJ. By targeting the MMEJ pathway, ART6043 may offer a strategy to overcome or delay the onset of such resistance.

Future Directions

Following the FTD , Artios plans to initiate a global randomized phase 2 study. This trial will further characterize the efficacy and safety of ART6043 in patients with BRCA-mutant HER2-negative breast cancer who are eligible for treatment with PARP inhibitors. The fast track program will allow for more frequent interactions with the FDA and potentially lead to priority review or accelerated approval if clinical benchmarks are met.

REFERENCES

1. Artios receives U.S. FDA fast track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer. News release. Artios Pharma. February 23, 2026. Accessed February 23, 2026. https://tinyurl.com/3t7w4623

2. Study of ART6043 in advanced/​metastatic solid tumors patients. ClinicalTrials.gov. Updated October 15, 2025. Accessed February 23, 2026. https://clinicaltrials.gov/study/NCT05898399